These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10077027)

  • 1. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
    Sharma R; Saini S; Ros PR; Hahn PF; Small WC; de Lange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK; Morris M; Lucas M
    J Magn Reson Imaging; 1999 Feb; 9(2):291-4. PubMed ID: 10077027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations.
    Harisinghani MG; Saini S; Weissleder R; Rubin D; deLange E; Harms S; Weinreb J; Small W; Sukerkar A; Brown JJ; Zelch J; Lucas M; Morris M; Hahn PF
    J Comput Assist Tomogr; 2001; 25(5):770-6. PubMed ID: 11584239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.
    Bernd H; De Kerviler E; Gaillard S; Bonnemain B
    Invest Radiol; 2009 Jun; 44(6):336-42. PubMed ID: 19661843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.
    Hudgins PA; Anzai Y; Morris MR; Lucas MA
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):649-56. PubMed ID: 11950660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging.
    Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK
    Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro.
    Müller K; Skepper JN; Posfai M; Trivedi R; Howarth S; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2007 Mar; 28(9):1629-42. PubMed ID: 17178155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications.
    Reimer P; Balzer T
    Eur Radiol; 2003 Jun; 13(6):1266-76. PubMed ID: 12764641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
    Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
    Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The endorem tolerance profile].
    Laniado M; Chachuat A
    Radiologe; 1995 Nov; 35(11 Suppl 2):S266-70. PubMed ID: 8588033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical evaluation of a new iron oxide MR contrast agent.
    McLachlan SJ; Morris MR; Lucas MA; Fisco RA; Eakins MN; Fowler DR; Scheetz RB; Olukotun AY
    J Magn Reson Imaging; 1994; 4(3):301-7. PubMed ID: 8061425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions.
    Ros PR; Freeny PC; Harms SE; Seltzer SE; Davis PL; Chan TW; Stillman AE; Muroff LR; Runge VM; Nissenbaum MA
    Radiology; 1995 Aug; 196(2):481-8. PubMed ID: 7617864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent.
    Bourrinet P; Bengele HH; Bonnemain B; Dencausse A; Idee JM; Jacobs PM; Lewis JM
    Invest Radiol; 2006 Mar; 41(3):313-24. PubMed ID: 16481915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10.
    Tatsumi Y; Tanigawa N; Nishimura H; Nomura E; Mabuchi H; Matsuki M; Narabayashi I
    Gastric Cancer; 2006; 9(2):120-8. PubMed ID: 16767368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties.
    Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD
    Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of MR liver specific contrast media.
    Bellin MF; Webb JA; Van Der Molen AJ; Thomsen HS; Morcos SK;
    Eur Radiol; 2005 Aug; 15(8):1607-14. PubMed ID: 15627176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging.
    Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD
    J Magn Reson Imaging; 1994; 4(3):309-14. PubMed ID: 8061426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenosis: superparamagnetic iron oxide-enhanced MR imaging.
    Storm BL; Abbitt PL; Allen DA; Ros PR
    AJR Am J Roentgenol; 1992 Aug; 159(2):333-5. PubMed ID: 1632350
    [No Abstract]   [Full Text] [Related]  

  • 20. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
    Islam T; Wolf G
    Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.